MET and hepatocellular carcinoma: DE605, a c‐Met inhibitor, acts synergistically with sorafenib to suppress HCC cells (Jiang et al., 2015); SU11274, another c‐Met inhibitor, and HGF‐neutralizing antibody reversed the invasion properties of sorafenib‐resistant HCC cells (Firtina Karagonlar et al., 2016).